GSK: trials of a low-carbon MDI

(CercleFinance.com) - GSK announces a major step towards its sustainability ambitions with the advancement of the low-carbon Ventolin program towards Phase III trials.


The group will begin Phase III trials of a low-carbon version of its metered-dose inhaler (MDI), Ventolin (salbutamol), in 2024, using a new-generation propellant.

It has the potential to reduce greenhouse gas emissions associated with inhaler use by around 90%, making a significant contribution to GSK's ambitious zero net emissions climate goals.

' Thirty-five million respiratory patients worldwide rely on this inhaler as a rescue medication. However, it accounts for almost half (49%) of GSK's carbon footprint, in addition to contributing to the carbon footprint of global healthcare systems' says the group.

Copyright (c) 2023 CercleFinance.com. All rights reserved.